Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina
Background: Medication-related osteonecrosis of the jaw (MRONJ) is an adverse effect associated with the use of antiresorptive/antiangiogenic medications. Few observational studies have been conducted in South America. Our aim was to describe patients with MRONJ from Córdoba, Argentina, focusing on...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2025
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/46061 |
| Aporte de: |
| id |
I10-R327-article-46061 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
osteoporosis neoplasms retrospective studies diphosphonate-associated osteonecrosis of the jaw osteonecrosis de los maxilares asociada a difosfonatos osteoporosis neoplasias estudios retrospectivos osteoporose neoplasias estudos retrospectivos osteonecrose dos maxilares associada a difosfonatos |
| spellingShingle |
osteoporosis neoplasms retrospective studies diphosphonate-associated osteonecrosis of the jaw osteonecrosis de los maxilares asociada a difosfonatos osteoporosis neoplasias estudios retrospectivos osteoporose neoplasias estudos retrospectivos osteonecrose dos maxilares associada a difosfonatos Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| topic_facet |
osteoporosis neoplasms retrospective studies diphosphonate-associated osteonecrosis of the jaw osteonecrosis de los maxilares asociada a difosfonatos osteoporosis neoplasias estudios retrospectivos osteoporose neoplasias estudos retrospectivos osteonecrose dos maxilares associada a difosfonatos |
| author |
Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René |
| author_facet |
Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René |
| author_sort |
Leonardi, Nicolás |
| title |
Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| title_short |
Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| title_full |
Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| title_fullStr |
Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| title_full_unstemmed |
Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina |
| title_sort |
drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in argentina |
| description |
Background: Medication-related osteonecrosis of the jaw (MRONJ) is an adverse effect associated with the use of antiresorptive/antiangiogenic medications. Few observational studies have been conducted in South America. Our aim was to describe patients with MRONJ from Córdoba, Argentina, focusing on demographic, pharmacological, and serological variables, as well as associated risk factors. Methods: We conducted a cross-sectional study involving MRONJ patients who visited two Oral Medicine Departments between 2016 and 2022. Chi-square tests and Student t-tests were used to compare proportions in categorical and quantitative variables. Additionally, we provided a review of the literature from the last 10 years. Results: A total of 53 patients were included in the study. There was a female predominance in the osteoporosis group. The average duration of antiresorptive treatment for osteoporosis was 10.43 years. Zoledronate was statistically associated with the development of MRONJ. The mandible was more frequently affected than the maxilla. Tooth extraction was the most common triggering factor, accounting for 75% of cases. Additionally, 43.4% of the patients were diagnosed with Stage 1 MRONJ. Conclusion: This subgroup of Argentinean MRONJ patients exhibits similar characteristics to those reported in studies worldwide. The development of MRONJ in osteoporotic females may be linked to inadequate control of antiresorptive therapy. It is essential for general dentists and physicians to recognize the risk of MRONJ in these individuals. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2025 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/46061 |
| work_keys_str_mv |
AT leonardinicolas drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT gilligangerardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT garolafederico drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT piemonteeduardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT panicorene drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT leonardinicolas drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT gilligangerardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT garolafederico drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT piemonteeduardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT panicorene drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT leonardinicolas drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT gilligangerardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT garolafederico drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT piemonteeduardo drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT panicorene drugrelatedjawosteonecrosisa6yearretrospectivestudyfromtwocentersinargentina AT leonardinicolas osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT gilligangerardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT garolafederico osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT piemonteeduardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT panicorene osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT leonardinicolas osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT gilligangerardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT garolafederico osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT piemonteeduardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT panicorene osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT leonardinicolas osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT gilligangerardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT garolafederico osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT piemonteeduardo osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT panicorene osteonecrosisdelosmaxilaresasociadaamedicamentosunestudioretrospectivode6anosdesdedoscentrosdeargentina AT leonardinicolas osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT gilligangerardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT garolafederico osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT piemonteeduardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT panicorene osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT leonardinicolas osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT gilligangerardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT garolafederico osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT piemonteeduardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT panicorene osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT leonardinicolas osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT gilligangerardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT garolafederico osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT piemonteeduardo osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina AT panicorene osteonecrosedosmaxilaresassociadaamedicamentosumestudoretrospectivode6anosemdoiscentrosdaargentina |
| first_indexed |
2025-08-10T05:18:27Z |
| last_indexed |
2025-08-10T05:18:27Z |
| _version_ |
1840044422768623616 |
| spelling |
I10-R327-article-460612025-06-26T19:09:18Z Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina Osteonecrosis de los maxilares asociada a medicamentos: un estudio retrospectivo de 6 años desde dos centros de argentina Osteonecrose dos maxilares associada a medicamentos: um estudo retrospectivo de 6 anos em dois centros da Argentina Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René Leonardi, Nicolás Gilligan, Gerardo Garola, Federico Piemonte, Eduardo Panico, René osteoporosis neoplasms retrospective studies diphosphonate-associated osteonecrosis of the jaw osteonecrosis de los maxilares asociada a difosfonatos osteoporosis neoplasias estudios retrospectivos osteoporose neoplasias estudos retrospectivos osteonecrose dos maxilares associada a difosfonatos Background: Medication-related osteonecrosis of the jaw (MRONJ) is an adverse effect associated with the use of antiresorptive/antiangiogenic medications. Few observational studies have been conducted in South America. Our aim was to describe patients with MRONJ from Córdoba, Argentina, focusing on demographic, pharmacological, and serological variables, as well as associated risk factors. Methods: We conducted a cross-sectional study involving MRONJ patients who visited two Oral Medicine Departments between 2016 and 2022. Chi-square tests and Student t-tests were used to compare proportions in categorical and quantitative variables. Additionally, we provided a review of the literature from the last 10 years. Results: A total of 53 patients were included in the study. There was a female predominance in the osteoporosis group. The average duration of antiresorptive treatment for osteoporosis was 10.43 years. Zoledronate was statistically associated with the development of MRONJ. The mandible was more frequently affected than the maxilla. Tooth extraction was the most common triggering factor, accounting for 75% of cases. Additionally, 43.4% of the patients were diagnosed with Stage 1 MRONJ. Conclusion: This subgroup of Argentinean MRONJ patients exhibits similar characteristics to those reported in studies worldwide. The development of MRONJ in osteoporotic females may be linked to inadequate control of antiresorptive therapy. It is essential for general dentists and physicians to recognize the risk of MRONJ in these individuals. Introducción: La osteonecrosis mandibular relacionada con medicamentos (MRONJ) es un efecto adverso asociado con el uso de medicamentos antirresortivos/antiangiogénicos. Se han realizado pocos estudios observacionales en América del Sur. Nuestro objetivo fue describir pacientes con MRONJ de Córdoba, Argentina, centrándonos en variables demográficas, farmacológicas y serológicas, así como en factores de riesgo asociados. Métodos: Realizamos un estudio transversal que incluyó pacientes con MRONJ que visitaron dos Departamentos de Medicina Oral entre 2016 y 2022. Se utilizaron pruebas de chi-cuadrado y pruebas t de Student para comparar proporciones en variables categóricas y cuantitativas. Además, proporcionamos una revisión de la literatura de los últimos 10 años. Resultados: Se incluyeron un total de 53 pacientes en el estudio. Hubo un predominio femenino en el grupo de osteoporosis. La duración promedio del tratamiento antirresortivo para osteoporosis fue de 10,43 años. El zoledronato se asoció estadísticamente con el desarrollo de MRONJ. La mandíbula se vio afectada con mayor frecuencia que el maxilar. La extracción dental fue el factor desencadenante más común, representando el 75% de los casos. Además, el 43,4% de los pacientes fueron diagnosticados con MRONJ Estadio 1. Conclusión: Este subgrupo de pacientes argentinos con MRONJ exhibe características similares a las reportadas en estudios a nivel mundial. El desarrollo de MRONJ en mujeres osteoporóticas puede estar vinculado a un control inadecuado de la terapia antirresortiva. Es esencial que los dentistas generales y los médicos reconozcan el riesgo de MRONJ en estos individuos. Introdução: A osteonecrose da mandíbula relacionada a medicamentos (MRONJ) é um efeito adverso associado ao uso de medicamentos antirreabsortivos/antiangiogênicos. Poucos estudos observacionais foram conduzidos na América do Sul. Nosso objetivo foi descrever pacientes com MRONJ de Córdoba, Argentina, com foco em variáveis demográficas, farmacológicas e sorológicas, bem como fatores de risco associados. Métodos: Realizamos um estudo transversal envolvendo pacientes com MRONJ que visitaram dois Departamentos de Medicina Oral entre 2016 e 2022. Testes qui-quadrado e testes t de Student foram usados para comparar proporções em variáveis categóricas e quantitativas. Além disso, fornecemos uma revisão da literatura dos últimos 10 anos. Resultados: Um total de 53 pacientes foram incluídos no estudo. Houve predominância do sexo feminino no grupo com osteoporose. A duração média do tratamento antirreabsortivo para osteoporose foi de 10,43 anos. O zoledronato foi estatisticamente associado ao desenvolvimento de MRONJ. A mandíbula foi mais frequentemente afetada do que a maxila. A extração dentária foi o fator desencadeante mais comum, respondendo por 75% dos casos. Além disso, 43,4% dos pacientes foram diagnosticados com MRONJ Estágio 1. Conclusão: Este subgrupo de pacientes argentinos com MRONJ exibe características semelhantes às relatadas em estudos em todo o mundo. O desenvolvimento de MRONJ em mulheres osteoporóticas pode estar relacionado ao controle inadequado da terapia antirreabsortiva. É essencial que dentistas e médicos generalistas reconheçam o risco de MRONJ nesses indivíduos. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2025-06-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/46061 10.31053/1853.0605.v82.n2.46061 Revista de la Facultad de Ciencias Médicas de Córdoba.; ##issue.vol## 82 ##issue.no## 2 (2025); 318-342 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 82 Núm. 2 (2025); 318-342 Revista da Faculdade de Ciências Médicas de Córdoba; v. 82 n. 2 (2025); 318-342 1853-0605 0014-6722 10.31053/1853.0605.v82.n2 spa https://revistas.unc.edu.ar/index.php/med/article/view/46061/49287 https://revistas.unc.edu.ar/index.php/med/article/view/46061/49288 Derechos de autor 2025 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |